One shot, no prior infection required, and it works.
Depois de anos de pesquisa e ensaios clínicos concluídos, o Instituto Butantan entregou à Anvisa a documentação completa para aprovação da Butantan-DV, uma vacina contra a dengue que, se aprovada, será a primeira de dose única no mundo. O pedido chega em um momento de urgência histórica: em 2024, o Brasil registrou 6,6 milhões de casos prováveis e quase seis mil mortes confirmadas pela doença. A ciência cumpriu sua parte; agora, o destino da vacina repousa nas mãos dos reguladores, dos gestores públicos e dos mecanismos mais lentos — porém igualmente essenciais — da saúde coletiva.
- O Brasil enfrentou em 2024 o pior surto de dengue de sua história, com 6,6 milhões de casos e 5.900 mortes confirmadas, tornando a aprovação de uma nova vacina uma questão de urgência nacional.
- A Butantan-DV se diferencia das vacinas já existentes por exigir apenas uma dose, o que poderia transformar radicalmente a velocidade e a escala das campanhas de vacinação no país.
- Os ensaios clínicos demonstraram 79,6% de eficácia contra casos sintomáticos e 89% de proteção contra a forma grave da doença, com resultados publicados no New England Journal of Medicine e no The Lancet Infectious Diseases.
- A produção do insumo farmacêutico ativo e da vacina final ocorre inteiramente no Brasil, eliminando dependências externas e facilitando o escalonamento caso haja aprovação e compra pelo SUS.
- A aprovação pela Anvisa é apenas o primeiro obstáculo: negociações de preço e integração ao sistema público de saúde podem adiar por meses a disponibilidade da vacina para a população.
O Instituto Butantan concluiu os ensaios clínicos da Butantan-DV e submeteu à Anvisa toda a documentação necessária para aprovação regulatória. Se aprovada, a vacina será a primeira contra a dengue a exigir apenas uma dose no mundo — uma distinção relevante em um país onde as campanhas de imunização precisam alcançar dezenas de milhões de pessoas.
As outras duas vacinas disponíveis no Brasil apresentam limitações importantes: a Dengvaxia só pode ser administrada a quem já teve dengue ao menos uma vez, e a Qdenga, embora de uso geral, exige múltiplas doses e está disponível em quantidade restrita pelo sistema público. A Butantan-DV mudaria esse cenário. Os resultados clínicos, publicados no New England Journal of Medicine e no The Lancet Infectious Diseases, indicam 79,6% de eficácia contra casos sintomáticos e 89% de proteção contra a dengue grave. O diretor do instituto, Esper Kallás, classificou o avanço como um dos maiores da história científica e sanitária do país.
O contexto torna o pedido ainda mais urgente. Em 2024, o Brasil registrou 6,6 milhões de casos prováveis de dengue e 5.900 mortes confirmadas — os números mais altos da história. Outros mil óbitos ainda estão sob investigação. A produção nacional do insumo e da vacina final representa uma vantagem logística concreta: sem dependência de fornecedores estrangeiros, o escalonamento da produção seria viável assim que houvesse demanda.
Ainda assim, a aprovação pela Anvisa não encerra o processo. Após a análise regulatória — que o instituto espera ser relativamente ágil —, será necessário negociar a incorporação da vacina ao SUS e definir um preço. Essas etapas burocráticas podem estender o caminho até a vacinação em massa por vários meses. O trabalho científico está feito; o que vem agora é mais lento, menos visível, mas igualmente decisivo.
This week, Brazil's Butantan Institute crossed a threshold it has been working toward for years. The paperwork is done. The clinical trials are finished. All the documentation needed to convince Brazil's health regulator—the National Health Surveillance Agency, known as Anvisa—that a new dengue vaccine is safe and effective has been submitted. Now comes the waiting.
The vaccine is called Butantan-DV, and if Anvisa approves it, the world will have something it has never had before: a single-dose dengue vaccine. Two other dengue vaccines already exist in Brazil. Dengvaxia can only be given to people who have already been infected with dengue at least once. Qdenga works in the general population and is available through Brazil's public health system, though in limited supply. But both require multiple doses. Butantan-DV would change that equation entirely.
The clinical trials wrapped up in June. The results have been published in major medical journals. In the New England Journal of Medicine, Butantan researchers reported that the vaccine prevents symptomatic dengue infection in 79.6 percent of cases. In another study, published in The Lancet Infectious Diseases, they showed it offers 89 percent protection against severe dengue—the form that kills people. The vaccine also proved safe. Esper Kallás, the institute's director, called it one of the greatest advances in the country's health and scientific history, and a significant international achievement.
The timing matters enormously. In 2024, Brazil recorded 6.6 million probable dengue cases. The death toll reached 5,900 confirmed deaths, with another thousand deaths still under investigation. These are the highest numbers in the country's history. The virus spreads through the bite of the Aedes aegypti mosquito, and in recent years, the explosions of cases have become harder to ignore or manage. A vaccine that requires only one dose could change the scale and speed of vaccination campaigns.
There is also a practical advantage built into this vaccine. Both the active pharmaceutical ingredient and the finished vaccine are manufactured in Brazil. If Anvisa approves Butantan-DV and the public health system decides to buy it, scaling up production to meet national demand should be straightforward. There are no supply chain complications, no dependence on foreign manufacturers. The entire operation can happen at home.
But approval is not the finish line. Gustavo Mendes, who oversees regulatory affairs, quality, and clinical trials at Butantan, said the institute expects Anvisa's review to move relatively quickly—it is, he noted, a smaller part of the overall process. The agency will likely have questions. Butantan will answer them. Then Anvisa will decide. No timeline has been announced. Even if everything goes smoothly, the vaccine will not immediately enter mass production. The public health system will need to decide whether it wants to purchase the vaccine, and a price will have to be negotiated. These discussions could stretch the process out by several more months.
For now, the institute has done what it can do. The science is solid. The documentation is complete. The need is undeniable. What happens next depends on regulators, bureaucrats, and the machinery of public health procurement—the slower, less visible part of the story, but no less important than the laboratory work that came before.
Notable Quotes
One of the greatest advances in the country's health and scientific history, and a significant international achievement.— Esper Kallás, director of Butantan Institute
The expectation is that Anvisa's response will be swift, because this is a smaller part of the overall process. We expect there will be questions we need to answer, and then they will analyze our responses for approval.— Gustavo Mendes, director of regulatory affairs at Butantan
The Hearth Conversation Another angle on the story
Why does a single dose matter so much? Isn't the difference between one shot and two just a matter of convenience?
It's more than convenience. In a country dealing with 6.6 million cases in a single year, the difference between one dose and two is the difference between reaching millions of people and reaching fewer. Vaccination campaigns move faster, cost less per person, and people are more likely to complete them. One dose is the difference between a vaccine that can actually scale and one that struggles with logistics.
The vaccine shows 79.6 percent efficacy against symptomatic cases. That sounds good, but it's not perfect. What about the people it doesn't protect?
You're right to notice that. No vaccine is perfect. But 79.6 percent means that in a vaccinated population, dengue transmission drops dramatically. And the 89 percent protection against severe disease—against the cases that kill people—that's where the real impact lives. You can get infected and have mild symptoms. You won't die. That's the promise.
Brazil already has two dengue vaccines approved. Why is this one different enough to matter?
The existing vaccines require multiple doses and have restrictions. Dengvaxia only works if you've already had dengue. Qdenga works for everyone but needs multiple visits to a clinic. Butantan-DV is one shot, no prior infection required, and it works. In a country where half the population lives in poverty and clinic visits are hard to arrange, that difference is enormous.
Even if Anvisa approves it tomorrow, you said it could take months before people actually get vaccinated. Why the delay?
Because approval is just the beginning. The government has to decide if it wants to buy the vaccine, how many doses, at what price. Those negotiations happen in rooms far from the laboratory. A vaccine that works means nothing if the system that distributes it doesn't have the money or the will to use it.
What happens if Anvisa says no?
Then Brazil keeps using the vaccines it has, and the dengue cases keep climbing. The institute would have to figure out what went wrong and try again. But the data is strong. The trials are done. The science is there. The question now is whether the system moves fast enough to match the scale of the problem.